Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.27% | -88.54% | -77.98% | -73.94% | -30.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.27% | -88.54% | -77.98% | -73.94% | -30.25% |
| Cost of Revenue | 40.10% | 43.88% | 49.85% | 47.36% | 46.00% |
| Gross Profit | -44.21% | -49.54% | -55.58% | -56.19% | -50.95% |
| SG&A Expenses | 13.61% | 10.44% | 13.72% | 13.59% | 17.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.52% | 37.89% | 42.96% | 40.56% | 40.18% |
| Operating Income | -38.80% | -42.29% | -47.31% | -47.11% | -43.76% |
| Income Before Tax | -50.57% | -58.59% | -63.91% | -45.73% | -32.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.57% | -58.59% | -63.91% | -45.73% | -32.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.57% | -58.59% | -63.91% | -45.73% | -32.88% |
| EBIT | -38.80% | -42.29% | -47.31% | -47.11% | -43.76% |
| EBITDA | -39.34% | -42.89% | -47.99% | -47.82% | -44.45% |
| EPS Basic | -44.91% | -58.13% | -59.30% | -31.70% | -9.70% |
| Normalized Basic EPS | -44.91% | -58.13% | -59.30% | -45.30% | -20.23% |
| EPS Diluted | -44.91% | -58.13% | -59.30% | -31.70% | -9.70% |
| Normalized Diluted EPS | -44.91% | -58.13% | -59.30% | -45.30% | -20.23% |
| Average Basic Shares Outstanding | 4.48% | 0.31% | 3.16% | 9.18% | 18.40% |
| Average Diluted Shares Outstanding | 4.48% | 0.31% | 3.16% | 9.18% | 18.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |